HK1182312A1 - Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders fzd8 fzd8 - Google Patents
Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders fzd8 fzd8Info
- Publication number
- HK1182312A1 HK1182312A1 HK13109606.2A HK13109606A HK1182312A1 HK 1182312 A1 HK1182312 A1 HK 1182312A1 HK 13109606 A HK13109606 A HK 13109606A HK 1182312 A1 HK1182312 A1 HK 1182312A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fzd8
- obesity
- related disorders
- extracellular
- fusion molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35921410P | 2010-06-28 | 2010-06-28 | |
PCT/US2011/042033 WO2012006027A1 (en) | 2010-06-28 | 2011-06-27 | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1182312A1 true HK1182312A1 (en) | 2013-11-29 |
Family
ID=44588169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13109606.2A HK1182312A1 (en) | 2010-06-28 | 2013-08-16 | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders fzd8 fzd8 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8431532B2 (xx) |
EP (1) | EP2585098B1 (xx) |
DK (1) | DK2585098T3 (xx) |
HK (1) | HK1182312A1 (xx) |
WO (1) | WO2012006027A1 (xx) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
JP5368798B2 (ja) | 2005-10-31 | 2013-12-18 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断し処置するための組成物および方法 |
PL2769729T3 (pl) | 2007-09-04 | 2019-09-30 | Compugen Ltd. | Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2013001517A1 (en) | 2011-06-30 | 2013-01-03 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
BR112014018481A2 (pt) | 2012-02-01 | 2017-07-04 | Compugen Ltd | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso |
EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
KR102162676B1 (ko) * | 2013-12-26 | 2020-10-07 | 인텔 코포레이션 | 상보형 터널링 fet 디바이스와 그 형성 방법 |
US10535770B2 (en) * | 2014-09-24 | 2020-01-14 | Intel Corporation | Scaled TFET transistor formed using nanowire with surface termination |
CA3021271A1 (en) * | 2016-04-25 | 2017-11-02 | Glaxosmithkline Intellectual Property Development Limited | Nope for treatment of pathological muscle loss and weakness |
WO2019028186A1 (en) * | 2017-08-01 | 2019-02-07 | Ankasa Regenerative Therapeutics, Inc. | WNT COMPOSITIONS AND METHODS OF TREATMENT FROM SERUM-FREE CULTURE CONDITIONS |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
GB9819681D0 (en) | 1998-09-09 | 1998-11-04 | Smithkline Beecham Plc | Novel compounds |
CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
GB0221952D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Forschungsstiftung | Wnt mediated ErbB1 signalling,compositions and uses related thereto |
US20040247593A1 (en) | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
AU2006207999A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
US20090311243A1 (en) * | 2005-05-30 | 2009-12-17 | Astrazeneca Ab | Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis |
WO2007030290A2 (en) * | 2005-09-07 | 2007-03-15 | Maine Medical Center Research | Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto |
JP5368798B2 (ja) | 2005-10-31 | 2013-12-18 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断し処置するための組成物および方法 |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CA2662041A1 (en) | 2006-09-08 | 2008-03-13 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
US8183207B2 (en) * | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
TWI535445B (zh) * | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
-
2011
- 2011-06-27 EP EP11730818.9A patent/EP2585098B1/en not_active Not-in-force
- 2011-06-27 US US13/169,900 patent/US8431532B2/en not_active Expired - Fee Related
- 2011-06-27 DK DK11730818.9T patent/DK2585098T3/da active
- 2011-06-27 WO PCT/US2011/042033 patent/WO2012006027A1/en active Application Filing
-
2013
- 2013-08-16 HK HK13109606.2A patent/HK1182312A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2585098A1 (en) | 2013-05-01 |
US20120003222A1 (en) | 2012-01-05 |
US8431532B2 (en) | 2013-04-30 |
DK2585098T3 (da) | 2014-11-03 |
EP2585098B1 (en) | 2014-08-27 |
WO2012006027A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1182312A1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders fzd8 fzd8 | |
HRP20181932T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
HK1252368A1 (zh) | 針對ox40l的免疫球蛋白單可變結構域抗體、構建體和治療用途 | |
HRP20170201T1 (hr) | Domene za vezivanje proteina za stabilizaciju funkcionalnih konformacijskih stanja gpcr-as i njihova uporaba | |
HK1176361A1 (zh) | 優先結合人 胞外域 的抗體及其用途 | |
IL228813B (en) | A polypeptide containing a first and second immunoglobulin each containing a single variable site and its use in the treatment of diseases | |
EP2774616A4 (en) | APPLICATION OF ROSEBURIA IN THE TREATMENT AND PREVENTION OF OBESITY-RELATED DISEASES | |
EP2265125A4 (en) | TOPICAL LFA-1 ANTAGONISTS USED IN LOCALIZED TREATMENT OF IMMUNE DISORDERS | |
EP2470565A4 (en) | MODIFIED MOLECULES WITH VARIABLE DOMAINS AND MANUFACTURING AND USE METHOD THEREFOR | |
EP2890370A4 (en) | AGENTS USEFUL FOR THE TREATMENT OF OBESITY, DIABETES AND RELATED DISORDERS | |
EP2512501A4 (en) | METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS | |
EP2563816A4 (en) | ANTI-ICAM-1 SINGLE DOMAIN ANTIBODIES AND USES THEREOF | |
PL2799445T3 (pl) | Polipeptyd blokujący integrynę do zastosowania w leczeniu reumatoidalnego zapalenia stawów | |
EP2531208A4 (en) | TREATMENT OF FIBROSIS RELATED DISORDERS USING FIBRONECTIN BINDING PROTEINS AND POLYPEPTIDES | |
HK1208159A1 (en) | Sorcs1 for use in the treatment of obesity and overweight sorcs1 | |
GB2500357B (en) | Combination and composition for treating obesity | |
EP2533794A4 (en) | PROTEIN DOMAINS AND ASSOCIATED USES | |
GB201105325D0 (en) | Modified nanog molecule and use in reprogramming | |
SI2663185T1 (sl) | Calebin A za uporabo pri zdravljenju vnetja in debelosti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190625 |